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Introduction
Gastric cancer is one of the most frequent cancers in worldwide which kill about 800 000 people annually [1] . It is a highly aggressive malignant disease with the overall 5 year survival rate (5YSR) of 24% [2] . The major reason for this poor outcome is that GC patients plays an important role in improving diagnosis and treatment of GC [4] . At present, one or epidemiological and clinical diagnostic screening [5] . Consequently, discovery of the valuable biomarkers of GC remains a worthy task.
The main function of mitochondria is to produce cellular energy which is essential for the survival of eukaryotic cells. Mitochondrial defects contribute to the development of numerous human diseases including cancer [6] . It is reported that mitochondrial damage is one of the most common characteristics of cancer cells, and mitochondrial deregulation plays a key role to trigger tumorigenesis and metastasis [7] . In the past decade, a series Together, these studies show that impaired mitochondrial function plays a pivotal role in the onset of contractile dysfunction associated with cancer. However, the complete identity of mitochondrial proteins involved in the GC development process remains unclear.
and widely used for quantitative proteomics [15, 16] . The isotopes can be incorporated metabolically as in SILAC or chemically as in isobaric labeling methods include isobaric one ( C or 15 indicating that this approach is applicable to quantitative proteomic studies.
mitochondrial biomarkers. Through this analysis we seek to highlight novel protein networks potentially underlying the dysregulation of mitochondrial proteins associated with GC. Our data revealed VDAC1 protein to be a potential biomarker for GC detection.
Materials and Methods

Patient samples
mucosa and no metastatic lymph nodes) and matched normal tissue samples (50-200 mg) were obtained from surgical resection specimens at the department of pathology, snap frozen in liquid nitrogen, and
Written informed consent was obtained from each patient before surgery. This study was approved by the
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry VO 4 ). Cell debris and nuclei were pelleted at 700 × g, followed by centrifugation at 5,000 × g to pellet a mitochondrial enriched fraction. Crude mitochondria and 0.2 mM Na VO 4 until use. until used. resuspended in 10 mM NH 4 fractions in total were collected and lyophilized.
(m/z 445.12002). The 20 most abundant peptide molecular ions dynamically determined from the MS scan 1.2.2.5) was used to identify the raw spectra acquired from precursor ions. Search parameters were set as between the GC and adjacent normal tissues (Table 1) . Of these, 15 proteins were down Cellular Physiology and Biochemistry phosphorylation, and a corresponding increase in glycolysis [27] have been observed in cancer cell mitochondrial. As a result, we would like to describe potential mitochondrial biomarkers for the early detection of gastric cancer. In order to thoroughly understand the molecular mechanisms associated with tumorigenesis and metastasis, a subcellular proteomics strategy has been applied to identify the cancer markers in mitochondria that relate to tumorigenesis and metastasis [28] . In this research, we used a Nycodenz density gradient approach for mitochondrial enrichment, and TMT technology combined with nano GC tissue. Although only 40.1% of the isolated proteins were assigned to be mitochondrial located, the percentage is higher than the general total cellular protein analysis (~5% of total proteins across normal and GC tissues were enriched.
The results suggested that current proteomic strategy is a potential tool for discovering valuable GC markers.
2+
agents use the mitochondrial VDAC 1 as their pharmacological target [41] . However, whether this mitochondrial protein plays a role in the carcinogenesis process in GC is unknown. Our of the relationship between VDAC1 and GC, suggesting that VDAC1 is a promising candidate for future biomarker development for gastric cancer.
promote tumor growth, independently of tumor angiogenesis [44] . In the present research, tissues, suggesting that deregulated cellular energetics was considered as an additional emerging hallmark of GC tissues. 
